https://www.selleckchem.com/pr....oducts/c-176-sting-i
Recent studies emphasize the importance of considering the metabolic status to develop personalized medicine approaches. This is especially relevant in prostate cancer (PCa), wherein the diagnostic capability of PSA dramatically drops when considering patients with PSA levels ranging 3-10ng/mL, the so-called "grey-zone". Hence, additional non-invasive diagnostic and/or prognostic PCa biomarkers are urgently needed, especially in the metabolic-status context. To assess the potential relation of urine In1-ghrelin (a ghrelin
Like
Comment
Share
